• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.

作者信息

Yang Yuan-Qin, Dong Wen-Jie, Yin Xiao-Fei, Xu Yan-Ni, Yang Yu, Wang Jiao-Jiao, Yuan Su-Jing, Xiao Jing, DeLong Jonathan Howard, Chu Liang, Xu Hai-Neng, Zhou Xiu-Mei, Wang Ru-Wei, Fang Ling, Liu Xin-Yuan, Zhang Kang-Jian

机构信息

Xinyuan Institute of Medicine and Biotechnology, Zhejiang Sci-Tech University, Hangzhou, 310018, China.

State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.

出版信息

Protein Cell. 2016 Jul;7(7):538-43. doi: 10.1007/s13238-016-0281-6.

DOI:10.1007/s13238-016-0281-6
PMID:27295261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4930771/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a7/4930771/c0d35f4557a5/13238_2016_281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a7/4930771/bafbb0b9cc0f/13238_2016_281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a7/4930771/c0d35f4557a5/13238_2016_281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a7/4930771/bafbb0b9cc0f/13238_2016_281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a7/4930771/c0d35f4557a5/13238_2016_281_Fig2_HTML.jpg

相似文献

1
Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.肿瘤细胞中PD-L1的上调需要免疫细胞与肿瘤细胞直接相互作用产生的干扰素相关分泌蛋白组。
Protein Cell. 2016 Jul;7(7):538-43. doi: 10.1007/s13238-016-0281-6.
2
Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses.受乳腺肿瘤影响的B细胞获得LAP/TGF-β和PD-L1表达并抑制抗肿瘤免疫反应。
Int Immunol. 2016 Sep;28(9):423-33. doi: 10.1093/intimm/dxw007. Epub 2016 Feb 19.
3
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.Eya3 通过丝氨酸磷酸酶介导的 PD-L1 上调促进乳腺癌相关免疫抑制。
J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.
4
Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.免疫组化分析作为预测患者对癌症治疗反应的指标：前景与挑战。
Curr Opin Immunol. 2017 Apr;45:60-72. doi: 10.1016/j.coi.2017.01.005. Epub 2017 Feb 20.
5
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.程序性细胞死亡配体1（PD-L1）表达并非尤因肉瘤的主要特征。
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26719. Epub 2017 Sep 4.
6
Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.伴有肿瘤性PD-L1表达的血管内大B细胞淋巴瘤尸检病例报告
J Clin Exp Hematop. 2018 Mar 16;58(1):32-35. doi: 10.3960/jslrt.17037. Epub 2018 Feb 8.
7
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.PDL1 通过保守序列基序发出信号，以克服干扰素介导的细胞毒性。
Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.
8
[Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].[程序性死亡受体配体1（PD-L1）表达的调控机制及其在免疫逃逸中的作用]
Gan To Kagaku Ryoho. 2017 Nov;44(11):967-971.
9
Immune regulation of canine tumour and macrophage PD-L1 expression.犬肿瘤和巨噬细胞 PD-L1 表达的免疫调节。
Vet Comp Oncol. 2017 Jun;15(2):534-549. doi: 10.1111/vco.12197. Epub 2016 Feb 4.
10
IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells.γ干扰素通过上调肿瘤细胞上的细胞间黏附分子-1（ICAM-1）克服PD-L1/PD1对嵌合抗原受体T细胞（CAR-T）疗法的抑制作用。
Signal Transduct Target Ther. 2021 Jan 7;6(1):20. doi: 10.1038/s41392-020-00357-7.

引用本文的文献

1
Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.将 PD-1/PD-L1 阻断与 I 型干扰素联合用于癌症治疗。
Front Immunol. 2023 Aug 24;14:1249330. doi: 10.3389/fimmu.2023.1249330. eCollection 2023.
2
HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas.HOXC6通过胶质瘤中的基因转录影响上皮-间质转化和免疫微环境。
Cancer Cell Int. 2022 Apr 29;22(1):170. doi: 10.1186/s12935-022-02589-9.
3
ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.

本文引用的文献

1
Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling.限制胆固醇生物合成通量会自发激活I型干扰素信号通路。
Cell. 2015 Dec 17;163(7):1716-29. doi: 10.1016/j.cell.2015.11.045. Epub 2015 Dec 10.
2
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.致癌激活 AKT-mTOR 通路对非小细胞肺癌 PD-L1 表达的调控。
Cancer Res. 2016 Jan 15;76(2):227-38. doi: 10.1158/0008-5472.CAN-14-3362. Epub 2015 Dec 4.
3
Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia.
ISG15 通路敲低通过下调 PDL-1 表达逆转胰腺癌细胞转化并减少小鼠胰腺肿瘤生长。
Cancer Immunol Immunother. 2019 Dec;68(12):2029-2039. doi: 10.1007/s00262-019-02422-9. Epub 2019 Nov 11.
4
Linking Autophagy and the Dysregulated NFκB/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications.癌症中自噬与失调的NFκB/SNAIL/YY1/RKIP/PTEN循环的关联：治疗意义
Crit Rev Oncog. 2018;23(5-6):307-320. doi: 10.1615/CritRevOncog.2018027212.
5
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.胶质母细胞瘤中联合基因介导的细胞毒性免疫治疗和免疫检查点阻断的临床前研究。
Neuro Oncol. 2018 Jan 22;20(2):225-235. doi: 10.1093/neuonc/nox139.
6
New Insights into the Role of Autophagy in Tumor Immune Microenvironment.自噬在肿瘤免疫微环境中的作用新见解
Int J Mol Sci. 2017 Jul 19;18(7):1566. doi: 10.3390/ijms18071566.
7
Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.抗癌免疫中的自噬机制：其在癌症治疗中的利弊
Int J Mol Sci. 2017 Jun 19;18(6):1297. doi: 10.3390/ijms18061297.
神经元干扰素-β-干扰素α受体缺乏导致路易体和帕金森病样痴呆。
Cell. 2015 Oct 8;163(2):324-39. doi: 10.1016/j.cell.2015.08.069.
4
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.在Eµ-TCL1慢性淋巴细胞白血病小鼠模型中，与衰老相关的免疫缺陷背景下PD-L1/PD-1介导的CD8 T细胞功能障碍机制。
Blood. 2015 Jul 9;126(2):212-21. doi: 10.1182/blood-2015-02-626754. Epub 2015 May 15.
5
Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.通过与CD11b阳性骨髓来源的基质细胞接触，免疫检查点调节因子PD-L1在肿瘤细胞上表达。
Cell Commun Signal. 2015 Feb 27;13:14. doi: 10.1186/s12964-015-0093-y.
6
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.人黑色素瘤细胞中程序性死亡受体配体1（PD-L1）的诱导性而非组成性表达依赖于核因子κB（NF-κB）的激活。
PLoS One. 2015 Apr 6;10(4):e0123410. doi: 10.1371/journal.pone.0123410. eCollection 2015.
7
T cell exclusion, immune privilege, and the tumor microenvironment.T 细胞排斥、免疫特权和肿瘤微环境。
Science. 2015 Apr 3;348(6230):74-80. doi: 10.1126/science.aaa6204.
8
Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.胃癌组织中 FOXP3+调节性 T 细胞浸润与 B7-H1 表达的相关性。
Exp Mol Pathol. 2014 Jun;96(3):284-91. doi: 10.1016/j.yexmp.2014.03.005. Epub 2014 Mar 20.
9
CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens.黑色素瘤细胞上的 CD271 是一种 IFN-γ 诱导的免疫抑制因子，可介导黑色素瘤抗原的下调。
J Invest Dermatol. 2014 May;134(5):1369-1377. doi: 10.1038/jid.2013.490. Epub 2013 Nov 13.
10
Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.在治疗过程中，干扰素诱导的程序性死亡配体1（PD-L1/B7-H1）在人类急性髓性白血病原始细胞上的表达增加。
Eur J Haematol. 2014 Mar;92(3):195-203. doi: 10.1111/ejh.12228. Epub 2013 Nov 26.